Under what circumstances will olaparib (olaparib, lipedro) be reimbursed by medical insurance?
Olaparib (Olaparib, Lipadro) is an important anti-tumor drug, suitable for treatment-naïve adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who carry germline or somatic BRCA mutations and achieve complete response or partial response after first-line platinum-containing chemotherapy. Maintenance therapy; or maintenance therapy for adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after achieving complete or partial response to platinum-containing chemotherapy; adult patients with metastatic castration-resistant prostate cancer who harbor germline or somatic BRCA mutations and have failed prior therapy.

Lynparza needs to be included in the national medical insurance directory, which is the basic prerequisite for it to be reimbursed by medical insurance. Patients must participate in basic medical insurance and be in normal payment status to enjoy medical insurance reimbursement.
When patients purchase Lynparza, they must have a prescription issued by a doctor; the drug must be purchased at a medical insurance designated hospital, or at a designated retail pharmacy with a prescription issued by a medical insurance designated hospital. Patients need to submit relevant diagnostic certificates, chemotherapy plans, BRCA gene testing reports and other information before each purchase of medicines for review and accounting by the medical insurance department;
If the medical insurance reimbursement conditions are met, the reimbursement ratio of Lynparza can reach 80%, that is, patients only need to pay 20% out of pocket.
To sum up, the medical insurance reimbursement of Lynparza (Olaparib, Lipadro) is restricted by a variety of conditions, including indications, medical insurance catalogue, patient medical insurance status, prescription requirements and drug purchase channels. Patients should fully understand and follow these conditions when purchasing and using Lynparza to ensure they can receive medical insurance reimbursement.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)